相似文献
1
The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.
Cell Mol Life Sci. 2022 May 9;79(6):285. doi: 10.1007/s00018-022-04321-2.
2
The NSD family of protein methyltransferases in human cancer.
Epigenomics. 2015 Aug;7(5):863-74. doi: 10.2217/epi.15.32. Epub 2015 May 5.
3
In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
BMC Struct Biol. 2014 Dec 12;14:25. doi: 10.1186/s12900-014-0025-x.
4
Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.
Nature. 2021 Feb;590(7846):498-503. doi: 10.1038/s41586-020-03069-8. Epub 2020 Dec 23.
5
Cancers and the NSD family of histone lysine methyltransferases.
Biochim Biophys Acta. 2011 Dec;1816(2):158-63. doi: 10.1016/j.bbcan.2011.05.004. Epub 2011 Jun 6.
6
The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.
Cold Spring Harb Perspect Med. 2017 Jun 1;7(6):a026708. doi: 10.1101/cshperspect.a026708.
7
The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition.
J Biol Chem. 2013 Feb 15;288(7):4692-703. doi: 10.1074/jbc.M112.426148. Epub 2012 Dec 26.
8
A Basic Post-SET Extension of NSDs Is Essential for Nucleosome Binding In Vitro.
J Biomol Screen. 2014 Jul;19(6):928-35. doi: 10.1177/1087057114525854. Epub 2014 Mar 4.
9
Structural insights into the regulation and the recognition of histone marks by the SET domain of NSD1.
Biochem Biophys Res Commun. 2011 Aug 26;412(2):214-9. doi: 10.1016/j.bbrc.2011.07.061. Epub 2011 Jul 22.
10
NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
Cancer Med. 2023 May;12(9):10961-10978. doi: 10.1002/cam4.5774. Epub 2023 Apr 16.
引用本文的文献
1
Fuelling the Fight from the Gut: Short-Chain Fatty Acids and Dexamethasone Synergise to Suppress Gastric Cancer Cells.
Cancers (Basel). 2025 Jul 28;17(15):2486. doi: 10.3390/cancers17152486.
2
Identification of SMYD2 as a candidate diagnostic and prognostic biomarker for gastric cancer.
Front Oncol. 2025 Jul 24;15:1617971. doi: 10.3389/fonc.2025.1617971. eCollection 2025.
3
RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications.
MedComm (2020). 2025 Aug 3;6(8):e70322. doi: 10.1002/mco2.70322. eCollection 2025 Aug.
4
NSD proteins in anti-tumor immunity and their therapeutic targeting by protein degraders.
Cell Mol Life Sci. 2025 Jun 30;82(1):268. doi: 10.1007/s00018-025-05806-6.
5
Transgenerational diabetogenic effects of preconception exposure to inorganic arsenic in C57BL/6 mice are associated with dysregulation of DNA methylation and gene expression in G1 and G2 offspring.
Arch Toxicol. 2025 Jun 12. doi: 10.1007/s00204-025-04107-y.
6
Genetic Markers of Spina Bifida: Enrichment of Pathogenic Variants and Variants of Uncertain Significance.
J Indian Assoc Pediatr Surg. 2025 Mar-Apr;30(2):163-169. doi: 10.4103/jiaps.jiaps_193_24. Epub 2025 Jan 29.
7
H3K36me2 methyltransferase NSD2/WHSC1 promotes triple-negative breast cancer metastasis via activation of ULK1-dependent autophagy.
Autophagy. 2025 Mar 25:1-19. doi: 10.1080/15548627.2025.2479995.
8
Differences between lung adenocarcinoma and lung squamous cell carcinoma: Driver genes, therapeutic targets, and clinical efficacy.
Genes Dis. 2024 Jul 11;12(3):101374. doi: 10.1016/j.gendis.2024.101374. eCollection 2025 May.
9
Comprehensive Analysis of Multi-Omics Data on RNA Polymerase as an Adverse Factor in Head and Neck Squamous Cell Carcinoma.
J Inflamm Res. 2025 Mar 1;18:3067-3091. doi: 10.2147/JIR.S496748. eCollection 2025.
10
Epigenetic Modifiers: Exploring the Roles of Histone Methyltransferases and Demethylases in Cancer and Neurodegeneration.
Biology (Basel). 2024 Dec 3;13(12):1008. doi: 10.3390/biology13121008.
本文引用的文献
1
A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization.
Nat Chem Biol. 2022 Jan;18(1):56-63. doi: 10.1038/s41589-021-00898-0. Epub 2021 Nov 15.
2
Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer.
Cell Death Dis. 2021 Oct 20;12(11):974. doi: 10.1038/s41419-021-04267-6.
3
Elevated expression of nuclear receptor-binding SET domain 3 promotes pancreatic cancer cell growth.
Cell Death Dis. 2021 Oct 6;12(10):913. doi: 10.1038/s41419-021-04205-6.
4
NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis.
Mol Cell. 2021 Nov 4;81(21):4481-4492.e9. doi: 10.1016/j.molcel.2021.08.034. Epub 2021 Sep 22.
5
Misleading Germ Cell Phenotype in Pulmonary NUT Carcinoma Harboring the ZNF532-NUTM1 Fusion.
Am J Surg Pathol. 2022 Feb 1;46(2):281-288. doi: 10.1097/PAS.0000000000001774.
6
The H3K36me2 methyltransferase NSD1 modulates H3K27ac at active enhancers to safeguard gene expression.
Nucleic Acids Res. 2021 Jun 21;49(11):6281-6295. doi: 10.1093/nar/gkab473.
7
NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein.
Oncogene. 2021 Apr;40(16):2952-2967. doi: 10.1038/s41388-021-01747-z. Epub 2021 Mar 19.
8
Profiling NSD3-dependent neural crest gene expression reveals known and novel candidate regulatory factors.
Dev Biol. 2021 Jul;475:118-130. doi: 10.1016/j.ydbio.2021.02.015. Epub 2021 Mar 8.
9
Chromatin dysregulation associated with NSD1 mutation in head and neck squamous cell carcinoma.
Cell Rep. 2021 Feb 23;34(8):108769. doi: 10.1016/j.celrep.2021.108769.
10
WHSC1/NSD2 regulates immune infiltration in prostate cancer.
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001374.
Zotero 插件